Abstract
Several research groups have begun to associate the Alzheimer Disease (AD) to Diabetes Mellitus (DM), obesity and cardiovascular disease. This relationship is so close that some authors have defined Alzheimer Disease as Type 3 Diabetes. Numerous studies have shown that people with type 2 diabetes have twice the incidence of sporadic AD.
Insulin deficiency or insulin resistance facilitates cerebral β-amyloidogenesis in murine model of AD, accompanied by a significant elevation in APP (Amyloid Precursor Protein) and BACE1 (β-site APP Cleaving Enzime 1). Similarly, deposits of Aβ produce a loss of neuronal surface insulin receptors and directly interfere with the insulin signaling pathway. Furthermore, as it is well known, these disorders are both associated to an increased cardiovascular risk and an altered cholesterol metabolism, so we have analyzed several therapies which recently have been suggested as a remedy to treat together AD and DM.
The aim of the present review is to better understand the strengths and drawbacks of these therapies.
Keywords: Type 2 Diabetes, Alzheimer's disease, Statins, Liraglutide, Metformin
Current Diabetes Reviews
Title:Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Volume: 9 Issue: 3
Author(s): Arianna Vignini, Alessia Giulietti, Laura Nanetti, Francesca Raffaelli, Lucia Giusti, Laura Mazzanti and Leandro Provinciali
Affiliation:
Keywords: Type 2 Diabetes, Alzheimer's disease, Statins, Liraglutide, Metformin
Abstract: Several research groups have begun to associate the Alzheimer Disease (AD) to Diabetes Mellitus (DM), obesity and cardiovascular disease. This relationship is so close that some authors have defined Alzheimer Disease as Type 3 Diabetes. Numerous studies have shown that people with type 2 diabetes have twice the incidence of sporadic AD.
Insulin deficiency or insulin resistance facilitates cerebral β-amyloidogenesis in murine model of AD, accompanied by a significant elevation in APP (Amyloid Precursor Protein) and BACE1 (β-site APP Cleaving Enzime 1). Similarly, deposits of Aβ produce a loss of neuronal surface insulin receptors and directly interfere with the insulin signaling pathway. Furthermore, as it is well known, these disorders are both associated to an increased cardiovascular risk and an altered cholesterol metabolism, so we have analyzed several therapies which recently have been suggested as a remedy to treat together AD and DM.
The aim of the present review is to better understand the strengths and drawbacks of these therapies.
Export Options
About this article
Cite this article as:
Vignini Arianna, Giulietti Alessia, Nanetti Laura, Raffaelli Francesca, Giusti Lucia, Mazzanti Laura and Provinciali Leandro, Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies, Current Diabetes Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573399811309030003
DOI https://dx.doi.org/10.2174/1573399811309030003 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Importance of Precision Medicine in Type 2 Diabetes Mellitus (T2DM): From Pharmacogenetic and Pharmacoepigenetic Aspects
Endocrine, Metabolic & Immune Disorders - Drug Targets Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus
Current Pharmaceutical Design Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Adipobiology of Diabetes Mellitus
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Current Medicinal Chemistry Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Targeting Peroxisome Proliferator-Activated Receptor Gamma for Generation of Antidiabetic Drug
Current Diabetes Reviews Editorial (Thematic Issue: What's Behind the Sex Gap in Cardiovascular Mortality?)
Current Pharmaceutical Design Investigation of the Metabolism of Rufinamide and Its Interaction with Valproate
Drug Metabolism Letters Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design Relationship between Fatty Acid Habitual Intake and Early Inflammation Biomarkers in Individuals with and without Type 2 Diabetes in Mexico
Endocrine, Metabolic & Immune Disorders - Drug Targets Cultured Adult Animal Neurons and Schwann Cells Give Us New Insights into Diabetic Neuropathy
Current Diabetes Reviews No Effect of Metformin on Ovarian Cancer Survival: A Systematic Review and Meta-Analysis of Cohort Studies
Current Pharmaceutical Design Adipose Tissue: The Link Between Obesity and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets An Overview of the Modulatory Effects of Oleic Acid in Health and Disease
Mini-Reviews in Medicinal Chemistry Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Antiprotozoal Agents: An Overview
Anti-Infective Agents in Medicinal Chemistry